Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05309915
Other study ID # SRN-707-002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date February 28, 2022
Est. completion date August 30, 2022

Study information

Verified date March 2024
Source Sirnaomics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single center study, randomized, to evaluate safety, tolerability, PK of single ascending dose of STP707 when administered by IV infusion in healthy subjects.


Description:

The study includes a screening period, admission, treatment period and follow up period. Four doses will be evaluated in 4 cohorts with up to 10 subjects per cohort. Each individual will receive a single dose of STP707 or placebo.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date August 30, 2022
Est. primary completion date August 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Male or female subjects 18 to 55 years of age, inclusive, at the time of signing the informed consent form (ICF). 2. Subjects must be in generally reasonable health with clinically insignificant screening and admission results (medical history, 12-lead electrocardiogram [ECG], physical examination, and laboratory tests), as determined by the Investigator. 3. Subjects must have a body mass index (BMI) >18 kg/m2 or <32 kg/m2 4. Subjects must have aspartate transaminase (AST), alanine transaminase (ALT), total bilirubin (TBIL), alkaline phosphatase (ALP), and glucose within upper limit of normal (ULN) range per reference laboratory reference ranges at Screening and Day -1 (Admission); one repeat laboratory analysis allowed per Investigator discretion. 5. Women of childbearing potential must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Day -1 (Admission), must not be actively breastfeeding, or planning to become pregnant during the study, and if not practicing abstinence from heterosexual activity that could result in conception (if this is the preferred and usual lifestyle of the subject), must agree to use 2 approved methods of birth control, during the study and for at least 60 days after the last dose of study drug, from the list below: 1. Condom plus diaphragm. 2. Condom plus cervical cap or female condom. 3. Hormonal contraceptives (stable dose for 28 days [4 weeks] prior to Screening) plus condom. 4. Intrauterine device (in place for 28 days [4 weeks] prior to Screening) plus condom. 5. Condom plus spermicide. 6. Partner vasectomy and use of barrier contraception methods (e.g., male condom, diaphragm, or sponge with spermicide). 6. Women of nonchildbearing potential must be either surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation/salpingectomy) or >1 year postmenopausal with follicle-stimulating hormone (FSH) in the postmenopausal range and not actively breastfeeding. 7. Men must agree to use barrier contraception (condom with spermicide) and refrain from sperm donation from the first dose of study drug until at least 90 days after the last dose of study drug. Post vasectomy, men must agree to use a barrier method (or partner barrier method) from the first dose of study drug until at least 90 days after the last dose of study drug. 8. Subjects must be informed of the nature of the study and must have agreed to and be able to read, review, and sign the study ICF prior to any study related procedure being performed. Exclusion Criteria: 1. Current or previous cancer, excluding basal cell carcinoma that has been in remission for >5 years prior to dosing and in situ cervical carcinoma; diabetes or known diagnosis of prediabetes; or any clinically significant cardiovascular (including ECG disturbances or history of rhythm disturbance/abnormality), endocrine, renal, hepatic, gastrointestinal, hematologic, respiratory, dermatological, neurological, psychiatric, or other disorder. 2. Hypertension, defined as blood pressure >140/90 mmHg (2 separate readings at least 15 minutes apart if first reading is not within normal range). a. NOTE: For the Screening blood pressure measurement, subjects should avoid smoking, caffeine, or exercise within 30 minutes prior to measurement; empty his or her bladder; then sit quietly in a comfortable chair with back support for at least 5 minutes prior to blood pressure measurement; and remain still during the measurement. Blood pressure should be measured with the subject's limb supported, with the blood pressure cuff at heart level, and with the correct cuff size. The measurement should not be taken over clothes. 3. Hyperlipidemia defined as 1. Cholesterol >300 mg/dL. 2. Low-density lipoprotein cholesterol >190 mg/dL. 3. And/or triglycerides >500 mg/dL. Note: Abnormal laboratory values may be repeated once at Investigator discretion. 4. Hemoglobin A1c (HbA1c) >6.5% at Screening. Note: Abnormal laboratory values may be repeated once at Investigator discretion. 5. Hemoglobin or hematocrit outside upper and lower limits of normal range per reference laboratory range at both Screening and Day -1 (Admission). 6. Creatinine kinase (CK) > ULN at Screening and Day-1 (Admission). 7. Serum creatinine above upper limit of normal range per reference laboratory reference ranges at both Screening and Day -1 (Admission). Note: Abnormal laboratory values may be repeated once at Investigator discretion. 8. Estimated glomerular filtration rate < 90 mL/min/1.73 m2 (calculated using the Chronic Kidney Disease Epidemiology Collaboration equation) at Screening and Day-1 (Admission). One retest of the exclusionary eGFR value is allowed at the discretion of the Investigator. 9. Known sensitivity or allergies to Trehalose; history of severe hypersensitivity to IV infusion. 10. Unwillingness to abstain from alcohol for 72 hours prior to dosing through EOS/ET. 11. Use of prescription or nonprescription drugs (excluding hormonal contraceptives), if clinically applicable, including vitamins, supplements, herbal preparations, and medicines that prolong QT/QTc within 7 days or 5 times longer than the half-life (whichever is longer) prior to the first dose of study drug through EOS (approximately 60 days). 12. Blood or plasma donation within 60 days prior to dosing. 13. Use of live and non-live vaccine within 30 days prior to the first dose of study drug or an intention to receive such a vaccine at any time during the study. 14. Received an investigational agent in another clinical study within 30 days prior to the first dose of study drug, or within 10 times longer than the half-life of the compound with which the subject was treated, whichever is longer. 15. Positive results of any of the virology tests (human immunodeficiency virus (HIV test), hepatitis B virus (HBsAg test) or hepatitis C virus (hepatitis C antibody test). 16. Diagnosed to be COVID-19 positive by polymerase chain reaction testing (SARS CoV 2 RT PCR positive) of a respiratory specimen (preferably a nasopharyngeal swab) on Day -2. NOTE: Rapid Antigen Test may be used if PCR testing is unavailable 17. Personal or family history of vascular aneurysms and disorders. 18. Personal or family history of long QT syndrome. 19. Personal or family history of hypokalemia. 20. Corrected QT interval using Fridericia's formula (> 450 msec) based on the average of triplicate ECGs. 21. History of alcoholism or abuse within 2 years prior to Screening. 22. Positive urine drug or breath alcohol screen at Screening or Day -1 (Admission). 23. Any condition that, in the opinion of the Investigator, would complicate or compromise the study data or the well-being of the subject.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
STP707
STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.

Locations

Country Name City State
United States Medpace Cincinnati Ohio

Sponsors (2)

Lead Sponsor Collaborator
Sirnaomics Medpace, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate safety & tolerability of STP707 when administered by IV in healthy subjects Number and percentage of subjects in total experiencing treatment-emergent (AEs) from baseline. 60 DAys
Primary Evaluate safety & tolerability of STP707 when administered by IV in healthy subjects Number and percentage of subjects in each dose cohort experiencing treatment-emergent (AEs) from baseline. 60 days
Secondary Evaluate (PK) of STP707 when administered by IV in healthy subjects PK parameters will be computed from individual plasma concentrations of STP707. Plasma concentrations will be assessed at each time point by study visit and cohort. 60 Days
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1